NF-kappaB/Rel is a family of transcription factors known to play important roles in control of expression of genes critical for growth, survival, adhesion, and immune and inflammatory responses. For example, work by the PI has demonstrated NF-kappaB/Rel factors regulate c-myc oncogene expression, implicated in control of proliferation and neoplastic transformation, as well as promote cell survival in B lymphocytes. In most cells other than B lymphocytes, NF-kappaB/Rel factors are inactive, sequestered in the cytoplasm. Aberrant activation of NF-kappaB/Rel in breast cancer has recently been demonstrated by the PI. Specifically, human breast tumor cell lines, primary human breast tumor tissue samples, and mammary tumors induced upon carcinogen treatment of rats were found to constitutively express high levels of nuclear NF-kappaB/Rel, whereas normal rat mammary glands and untransformed breast epithelial cells contained the expected low basal levels. Inhibition of this activity in breast cancer cells in culture led to apoptosis. Furthermore, activation of NFkappaB/Rel was found to precede tumor formation in the rat model, and upon carcinogen-induced transformation of human mammary epithelial cells. Here, experiments are proposed to test the hypothesis that aberrant activation of nuclear NF-kappaB/Rel activity plays a significant role in the pathogenesis of breast cancer.
Specific aims are to: 1) Determine the functional role of aberrant NF-kappaB/Rel expression in breast cancer cells testing effects on proliferation, viability and neoplastic transformation using cells in culture and transgenic mouse models; 2) Determine the mechanism of constitutive NF-kappaB/Rel activation in breast cancer; 3) Determine the functional role of the c-myc oncogene as a target of NF-kappaB/Rel activation in development of breast neoplasias. 4) Determine whether aberrant activation of NF-kappaB/Rel occurs prior to neoplastic transformation in human breast disease. The results of these studies will provide important information on the mechanism and role of aberrant NF-kappaB/Rel factor expression in the pathogenesis of breast disease, and on the potential use of these factors as new therapeutic targets in novel treatment modalities of breast disease. Lastly, given the extensive role of Rel factors, the findings of these studies have potential relevance to cancers of other cellular origin, as well as to a wide spectrum of diseases, including AIDS, arthritis, atherosclerosis, and autoimmunity.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA082742-01
Application #
2896824
Study Section
Metabolic Pathology Study Section (MEP)
Program Officer
Gallahan, Daniel L
Project Start
1999-09-01
Project End
2004-06-30
Budget Start
1999-09-01
Budget End
2000-06-30
Support Year
1
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Boston University
Department
Biochemistry
Type
Schools of Medicine
DUNS #
604483045
City
Boston
State
MA
Country
United States
Zip Code
02118
Bais, Manish V; Nugent, Matthew A; Stephens, Danielle N et al. (2012) Recombinant lysyl oxidase propeptide protein inhibits growth and promotes apoptosis of pre-existing murine breast cancer xenografts. PLoS One 7:e31188
Sato, Seiichi; Trackman, Philip C; Maki, Joni M et al. (2011) The Ras signaling inhibitor LOX-PP interacts with Hsp70 and c-Raf to reduce Erk activation and transformed phenotype of breast cancer cells. Mol Cell Biol 31:2683-95
Sanchez-Morgan, Nuria; Kirsch, Kathrin H; Trackman, Philip C et al. (2011) The lysyl oxidase propeptide interacts with the receptor-type protein tyrosine phosphatase kappa and inhibits *-catenin transcriptional activity in lung cancer cells. Mol Cell Biol 31:3286-97
Vora, Siddharth R; Guo, Ying; Stephens, Danielle N et al. (2010) Characterization of recombinant lysyl oxidase propeptide. Biochemistry 49:2962-72
Min, Chengyin; Zhao, Yingshe; Romagnoli, Mathilde et al. (2010) Lysyl oxidase propeptide sensitizes pancreatic and breast cancer cells to doxorubicin-induced apoptosis. J Cell Biochem 111:1160-8
Min, Chengyin; Yu, Ziyang; Kirsch, Kathrin H et al. (2009) A loss-of-function polymorphism in the propeptide domain of the LOX gene and breast cancer. Cancer Res 69:6685-93
Zhao, Yingshe; Min, Chengyin; Vora, Siddharth R et al. (2009) The lysyl oxidase pro-peptide attenuates fibronectin-mediated activation of focal adhesion kinase and p130Cas in breast cancer cells. J Biol Chem 284:1385-93
Palamakumbura, A H; Vora, S R; Nugent, M A et al. (2009) Lysyl oxidase propeptide inhibits prostate cancer cell growth by mechanisms that target FGF-2-cell binding and signaling. Oncogene 28:3390-400
Hurtado, Paola A; Vora, Siddharth; Sume, Siddika Selva et al. (2008) Lysyl oxidase propeptide inhibits smooth muscle cell signaling and proliferation. Biochem Biophys Res Commun 366:156-61
Min, Chengyin; Eddy, Sean F; Sherr, David H et al. (2008) NF-kappaB and epithelial to mesenchymal transition of cancer. J Cell Biochem 104:733-44

Showing the most recent 10 out of 28 publications